<DOC>
	<DOCNO>NCT01883414</DOCNO>
	<brief_summary>Up 25 subject enrol . Enrolled subject receive Ulthera® treatment one half surgical scar . Follow visit occur 30 , 90 180 day treatment . Study image obtain treatment , immediately treatment follow-up visit .</brief_summary>
	<brief_title>Feasibility Study : Evaluation Ulthera® System Improvement Surgical Scars .</brief_title>
	<detailed_description>This prospective , single-center , pilot clinical trial evaluate efficacy Ulthera® system improve appearance scar tissue neck , abdomen back . Changes baseline Patient Observer Scar Assessment Scale score assess study follow-up visit . Images obtain prior treatment follow visit . Patient satisfaction questionnaire also obtain .</detailed_description>
	<criteria>1 . Male female , age 18 70 year . 2 . Subject good health . 3 . Subjects regularly shape surgical scar chest , abdomen back least 4 cm long , wide 1 cm , least 6 month old . 4 . Understands accepts obligation undergo procedure area treat followup period . 5 . Willingness ability comply protocol requirement , include return followup visit abstain exclusionary procedure duration study . 6 . Subjects childbearing potential must negative urine pregnancy test result must lactate Screening Visit willing able use acceptable method birth control ( e.g . barrier method use spermicidal agent , hormonal method , IUD , surgical sterilization , abstinence ) study . Women consider childbearing potential one follow condition document medical history : Postmenopausal least 12 month prior study ; Without uterus and/or ovary ; Bilateral tubal ligation least six month prior study enrollment . 1 . Presence active systemic local skin disease may affect wound healing . 2 . Allergy pain medication use study ( lidocaine , NSAIDs , narcotic , etc . ) 3 . Severe solar elastosis . 4 . Open wound lesion area ( ) treat . 5 . Severe cystic acne area ( ) treat . 6 . Presence metal stent implant area ( ) treat . 7 . Inability understand protocol give inform consent . 8 . Microdermabrasion , prescription level glycolic acid treatment treatment area ( ) within three month prior study participation study . 9 . Intralesional kenalog past 6 month . 10 . History chronic drug alcohol abuse . 11 . History autoimmune disease . 12 . Concurrent therapy , investigator 's opinion , would interfere evaluation safety efficacy study device . 13 . Subjects anticipate need surgery overnight hospitalization study . 14 . Subjects , investigator 's opinion , history poor cooperation , noncompliance medical treatment , unreliability . 15 . Concurrent enrollment study involve use investigational device drug . 16 . Current smoker history smoking last year . 17 . History follow treatment area ( ) treat : 1 . Skin tighten procedure within past year ; 2 . Injectable filler type within past : . 12 month Hyaluronic acid filler ( e.g . Restylane ) ii . 12 month Ca Hydroxyapatite filler ( e.g . Radiesse ) iii . 24 month PolyLLactic acid filler ( e.g . Sculptra ) iv . Ever permanent filler ( e.g . Silicone , ArteFill ) c. Neurotoxins within past three month ; d. Ablative resurface laser treatment ; e. Nonablative , rejuvenative laser light treatment within past six month ; f. Surgical dermabrasion deep peel ; g. Any history contour thread . 18 . History use follow prescription medication : 1 . Accutane systemic retinoids within past six month ; 2 . Topical Retinoids within past two week ; 3 . Antiplatelet agents/Anticoagulants ( Coumadin , Heparin , Plavix , etc . ) ; 4 . Psychiatric drug investigator opinion would impair subject understand protocol requirement understand signing informed consent . 5 . Subjects immunocompromised immunosuppressive therapy 19 . Subjects immunocompromised immunosuppressive therapy 20 . History keloid</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Ulthera , Ultherapy , Surgical scar , scar ,</keyword>
</DOC>